Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Advanced Neuromuscular Medicine Fellowship, Duke University School of Medicine 2016 - 2017
  • Neuromuscular Medicine Fellowship, Neurology, Duke University School of Medicine 2015 - 2016
  • Neurology Residency, Adult Neurology, University of Maryland School of Medicine 2012 - 2015
  • Internship, Medicine, University of Maryland School of Medicine 2011 - 2012
  • M.D., Thomas Jefferson University 2011
• 

  Previous Appointments & Affiliations

  • Assistant Professor of Neurology, Neurology, Neuromuscular Disease, Neurology 2018 - 2020
  • Medical Instructor in the Department of Neurology, Neurology, General & Community Neurology, Neurology 2017 - 2018
• Research
• 

  Selected Grants

  • An Ascending, Single and Multiple Dose(s), Double-Blind, Randomized, Placebo Controlled Study Assessing the Safety, Tolerability, and Pharmacokinetics of OV329 in Healthy Male and Female Participants awarded by Ovid Therapeutics 2022 - 2025
  • Healthy Volunteer Study of CSF fluid and Oral Bioavailability of RR-HNK awarded by National Institutes of Health 2021 - 2024
  • PTN2: Trial Designs for Dosing/Safety and Efficacy in Pediatric Therapeutics_TO5; PTN-TBS02, Adult Terbutaline - DUK99 awarded by DCRI-Duke-Site 2022 - 2024
  • Phase I Single Ascending Dose and Multiple Ascending Dose Study of 2R,6R-Hydroxynorketamine awarded by National Institutes of Health 2018 - 2023
  • 18-0006 Mod 6 (EA) awarded by National Institute of Allergy and Infectious Diseases 2019 - 2023
  • Phase 1 Clinical Trials for Development of Neurotherapeutics Performance awarded by National Institutes of Health 2016 - 2023
  • Evaluation of the iMOST X Morphology Flagging awarded by Essenlix Corporation 2022 - 2023
  • Real World Outcomes of Surgical and Medical Management in Myasthenia Gravis awarded by American Academy of Neurology 2019 - 2022
  • Evaluation of GIMate Handheld Hydrogen Breath Monitor for Diagnosis of Lactose Malabsorption awarded by Vivante Health 2021 - 2022
  • RTOP 18-0006 Option 1 / Protocol Implementation awarded by National Institute of Allergy and Infectious Diseases 2019 - 2022
  • Phase 1 single-ascending dose study of the safety and pharmacokinetics of 24 hour intravenous 5-HTP (EVX-301) awarded by EVECXIA Therapeutics 2020
  • AANEM Autoimmune Neuromuscular Disorders Fellowship awarded by AANEM Foundation for Research & Education 2017 - 2018
• 

  External Relationships

  • Ocaro Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Signant Health
  • Tellus Therapeutics, Inc.
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Lodise TP, O’Donnell JN, Balevic S, Liu X, Gu K, George J, et al. Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults. Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0093622.
       Full Text  Link to Item
    • Lodise TP, O’Donnell JN, Raja S, Guptill JT, Zaharoff S, Schwager N, et al. Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers. Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0093522.
       Full Text  Link to Item
    • Raja S. Steroid use and perioperative complications of thymectomy in myasthenia gravis. Ann Thorac Surg. 2022 Dec 2;
       Full Text  Link to Item
    • Rumsey JW, Lorance C, Jackson M, Sasserath T, McAleer CW, Long CJ, et al. Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating Neuropathies. Adv Ther (Weinh). 2022 Jun;5(6).
       Full Text  Link to Item
    • Raja SM, Guptill JT, Juel VC, Walter EB, Cohen-Wolkowiez M, Hill H, et al. First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Doses of NTM-1633, a Novel Mixture of Monoclonal Antibodies against Botulinum Toxin E. Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0173221.
       Full Text  Link to Item
    • Balevic SJ, Raja SM, Randell R, Deye GA, Conrad T, Nakamura A, et al. Adverse Reactions in a Phase 1 Trial of the Anti-Malarial DM1157: An Example of Pharmacokinetic Modeling and Simulation Guiding Clinical Trial Decisions. Infect Dis Ther. 2022 Apr;11(2):841–52.
       Full Text  Link to Item
    • Raja SM, Guptill JT, McConnell A, Al-Khalidi HR, Hartwig MG, Klapper JA. Perioperative Outcomes of Thymectomy in Myasthenia Gravis: A Thoracic Surgery Database Analysis. Ann Thorac Surg. 2022 Mar;113(3):904–10.
       Full Text  Link to Item
    • Mathews SC, Templeton S, Taylor SK, Harris S, Stewart M, Raja SM. Evaluation of a Digital Handheld Hydrogen Breath Monitor to Diagnose Lactose Malabsorption: Interventional Crossover Study. Jmir Form Res. 2021 Oct 18;5(10):e33009.
       Full Text  Link to Item
    • Hobson-Webb LD, Zwelling PJ, Raja SS, Pifer AN, Kishnani PS. Quantitative muscle ultrasound and electrical impedance myography in late onset Pompe disease: A pilot study of reliability, longitudinal change and correlation with function. Mol Genet Metab Rep. 2021 Sep;28:100785.
       Full Text  Link to Item
    • Guptill JT, Raja SM, Juel VC, Walter EB, Cohen-Wolkowiez M, Hill H, et al. Safety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0232920.
       Full Text  Link to Item
    • Guptill JT, Barfield R, Chan C, Russo MA, Emmett D, Raja S, et al. Reduced plasmablast frequency is associated with seronegative myasthenia gravis. Muscle Nerve. 2021 Apr;63(4):577–85.
       Full Text  Link to Item
    • Li Y, Emmett CD, Cobbaert M, Sanders DB, Juel VC, Hobson-Webb LD, et al. Knowledge and perceptions of the COVID-19 pandemic among patients with myasthenia gravis. Muscle Nerve. 2021 Mar;63(3):357–64.
       Full Text  Link to Item
    • Sanders DB, Raja SM, Guptill JT, Hobson-Webb LD, Juel VC, Massey JM. The Duke myasthenia gravis clinic registry: I. Description and demographics. Muscle Nerve. 2021 Feb;63(2):209–16.
       Full Text  Link to Item
    • Van Eldik LJ, Sawaki L, Bowen K, Laskowitz DT, Noveck RJ, Hauser B, et al. First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers. Clin Pharmacol Drug Dev. 2021 Feb;10(2):131–43.
       Full Text  Link to Item
    • Li Y, Guptill JT, Russo MA, Howard JF, Massey JM, Juel VC, et al. Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis. J Neuroimmunol. 2020 Aug 15;345:577279.
       Full Text  Link to Item
    • Yi JS, Russo MA, Raja S, Massey JM, Juel VC, Shin J, et al. Inhibition of the transcription factor ROR-γ reduces pathogenic Th17 cells in acetylcholine receptor antibody positive myasthenia gravis. Exp Neurol. 2020 Mar;325:113146.
       Full Text  Link to Item
    • Raja SM, Howard JF, Juel VC, Massey JM, Chopra M, Guptill JT. Clinical outcome measures following plasma exchange for MG exacerbation. Ann Clin Transl Neurol. 2019 Oct;6(10):2114–9.
       Full Text  Link to Item
    • Raja SM, Sanders DB, Juel VC, Harati Y, Smith AG, Pascuzzi R, et al. Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia. Muscle Nerve. 2019 Sep;60(3):292–8.
       Full Text  Link to Item
    • Gwathmey KG, Sadjadi R, Horton WB, Conaway MR, Barnett-Tapia C, Bril V, et al. Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy: CAPPRI. Neurology. 2018 Jun 5;90(23):e2034–41.
       Full Text  Link to Item
    • Guptill JT, Raja S, Sanders DB, Narayanaswami P. Comparative effectiveness clinical trials to advance treatment of myasthenia gravis. Ann N Y Acad Sci. 2018 Feb;1413(1):69–75.
       Full Text  Link to Item
    • Sanders DB, Guptill JT, Aleš KL, Hobson-Webb LD, Jacobus DP, Mahmood R, et al. Reliability of the triple-timed up-and-go test. Muscle Nerve. 2018 Jan;57(1):136–9.
       Full Text  Link to Item
    • Guptill JT, Raja SM, Boakye-Agyeman F, Noveck R, Ramey S, Tu TM, et al. Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects. J Clin Pharmacol. 2017 Jun;57(6):770–6.
       Full Text  Link to Item
    • Yi JS, Russo MA, Massey JM, Juel V, Hobson-Webb LD, Gable K, et al. B10 Cell Frequencies and Suppressive Capacity in Myasthenia Gravis Are Associated with Disease Severity. Front Neurol. 2017;8:34.
       Full Text  Open Access Copy  Link to Item
    • Chen S, Fu L, Raja SM, Yue P, Khuri FR, Sun S-Y. Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis. Mol Cancer. 2010 Jan 29;9:23.
       Full Text  Link to Item
    • Chen S, Fu L, Raja SM, Yue P, Peterson YK, Khuri FR, et al. Differential roles of DR4, DR5 and c-FLIP in regulation of geranylgeranyltransferase I inhibitor-induced augmentation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Research. 2009 May 1;69.
       Link to Item
    • Raja SM, Chen S, Yue P, Acker TM, Lefkove B, Arbiser JL, et al. The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. Mol Cancer Ther. 2008 Jul;7(7):2212–23.
       Full Text  Link to Item

  • Conference Papers

    • Gable K, Yi J, Russo M, Emmett D, Gonzalez N, Raja S, et al. Enhanced CD4 and CD8 T cell responses in Chronic Inflammatory Demyelinating Polyneuropathy. In: Journal of the Peripheral Nervous System. 2021. p. 405–405.
       Link to Item
    • Raja S, Sanders D, Guptill J, Hobson-Webb L, Juel V, Massey J. Analysis of the Duke Myasthenia Gravis (MG) Clinic Registry: Thymectomy. In: Neurology. 2021.
       Link to Item
    • Rumsey J, Lorance C, Jackson M, Sasserath T, McAleer C, Long C, et al. CIDP patient serum triggers complement activation and functional deficits in motoneurons blocked by anti-C1s therapeutic. In: Journal of the Peripheral Nervous System. 2021. p. 320–320.
       Link to Item
    • Sanders D, Raja S, Guptill J, Hobson-Webb L, Juel V, Massey J. Analysis of the Duke Myasthenia Gravis (MG) Clinic Registry: Demographic and Clinical Characteristics. In: Neurology. 2020.
       Link to Item
    • Raja S, Juel V, Massey J, Hobson-Webb L, Guptill J, Gable K, et al. Lambert-Eaton Myasthenia With and Without Cancer: Clinical Characteristics and Long-term Survival. In: Neurology. LIPPINCOTT WILLIAMS & WILKINS; 2018.
       Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.